JP2006505587A5 - - Google Patents

Download PDF

Info

Publication number
JP2006505587A5
JP2006505587A5 JP2004546863A JP2004546863A JP2006505587A5 JP 2006505587 A5 JP2006505587 A5 JP 2006505587A5 JP 2004546863 A JP2004546863 A JP 2004546863A JP 2004546863 A JP2004546863 A JP 2004546863A JP 2006505587 A5 JP2006505587 A5 JP 2006505587A5
Authority
JP
Japan
Prior art keywords
hydroalcoholic gel
therapeutic agent
phosphodiesterase inhibitor
gel
type phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004546863A
Other languages
English (en)
Other versions
JP2006505587A (ja
Filing date
Publication date
Priority claimed from US10/273,484 external-priority patent/US20030139384A1/en
Application filed filed Critical
Publication of JP2006505587A publication Critical patent/JP2006505587A/ja
Publication of JP2006505587A5 publication Critical patent/JP2006505587A5/ja
Pending legal-status Critical Current

Links

Claims (6)

  1. 雄性対象における性的遂行能力の治療に役立つ薬剤の効率を向上させるための水性アルコール性ゲルであって、
    前記ゲルは、テストステロン合成経路中のステロイド、1種以上のC1〜C4アルコール、透過促進剤、増粘剤および水を含有し、
    前記薬剤が、V型ホスホジエステラーゼ阻害薬であることを特徴とする水性アルコール性ゲル。
  2. 重量基準で、
    (a)テストステロン0.1%から10%、
    (b)ミリスチン酸イソプロピル0.1%から5%、
    (c)ポリアクリル酸0.1%から5%、および
    (d)エタノール30%から約98%
    を含有する請求項1記載の水性アルコール性ゲル。
  3. 前記薬剤が、クエン酸シルデナフィル、その塩またはその鏡像異性体であることを特徴とする請求項1または2記載の水性アルコール性ゲル。
  4. 雄性対象における性的遂行能力の治療薬であって、
    請求項1〜3のいずれかに記載の水性アルコール性ゲルと、V型ホスホジエステラーゼ阻害薬との組み合わせを含み、
    前記水性アルコール性ゲルが、前記対象の皮膚に投与される治療薬。
  5. 前記水性アルコール性ゲルと、前記V型ホスホジエステラーゼ阻害薬を含む薬剤とを含むキットとして提供される請求項4記載の治療薬。
  6. 前記V型ホスホジエステラーゼ阻害薬が、クエン酸シルデナフィル、その塩またはその鏡像異性体であることを特徴とする請求項4または5記載の治療薬。
JP2004546863A 2002-10-18 2003-10-16 男性における勃起機能不全を治療し、性欲を増進する方法 Pending JP2006505587A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/273,484 US20030139384A1 (en) 2000-08-30 2002-10-18 Method for treating erectile dysfunction and increasing libido in men
PCT/US2003/032597 WO2004037173A2 (en) 2002-10-18 2003-10-16 Method for treating erectile dysfunction and increasing libido in men

Publications (2)

Publication Number Publication Date
JP2006505587A JP2006505587A (ja) 2006-02-16
JP2006505587A5 true JP2006505587A5 (ja) 2006-11-30

Family

ID=32174519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546863A Pending JP2006505587A (ja) 2002-10-18 2003-10-16 男性における勃起機能不全を治療し、性欲を増進する方法

Country Status (7)

Country Link
US (3) US20030139384A1 (ja)
EP (1) EP1551416A4 (ja)
JP (1) JP2006505587A (ja)
AU (1) AU2003277388A1 (ja)
CA (1) CA2502607A1 (ja)
MX (1) MXPA05004093A (ja)
WO (1) WO2004037173A2 (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
KR20050045946A (ko) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
PT1530965E (pt) 2003-11-11 2006-05-31 Udo Mattern Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
KR101292492B1 (ko) 2004-05-11 2013-08-01 이모셔널 브레인 비.브이. 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
JP2008534505A (ja) * 2005-03-25 2008-08-28 メルク エンド カムパニー インコーポレーテッド テストステロンサプリメントおよび5アルファ−レダクターゼインヒビターによる男性の治療方法
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
MX2007015255A (es) * 2005-06-03 2008-02-22 Acrux Dds Pty Ltd Metodo y composicion para administracion transdermica de un farmaco.
NZ563946A (en) * 2005-06-03 2012-02-24 Acrux Dds Pty Ltd Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla
GEP20125432B (en) * 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
PT2068825E (pt) 2006-10-04 2011-02-11 M & P Patent Ag Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
MX2009008995A (es) * 2007-03-23 2009-09-03 Unimed Pharmaceuticals Llc Composiciones y metodos para tratar hipogonadismo pediatrico.
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
CN102196821A (zh) * 2008-10-31 2011-09-21 莫贝里德尔马公司 包含至少两种渗透增强剂组合的局部组合物
JP2010163425A (ja) * 2008-12-18 2010-07-29 Daiichi Sankyo Healthcare Co Ltd ホスホジエステラーゼ5阻害剤とパンテチンを含有する医薬組成物
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
EP2640398A4 (en) 2010-11-18 2014-05-14 White Mountain Pharma Inc METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS
TWI422399B (zh) * 2011-01-21 2014-01-11 Tritech Biopharmaceuticals Co Ltd 促進第五型磷酸二酯酶抑制劑經皮吸收的醫藥組成物
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
HUE041292T2 (hu) * 2011-12-26 2019-05-28 Tritech Biopharmaceuticals Co Ltd Eljárás és feljavított gyógyszerészeti kompozíció PDE-5 inhibitor transzdermális átvitelének erõsítésére
US20150290217A1 (en) * 2012-11-21 2015-10-15 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
WO2014080282A2 (en) * 2012-11-22 2014-05-30 Trimel Biopharma Srl One-and two-point titration methods to determine daily treatment regimens to treat hypogonadism or male testosterone deficiency with an intranasal testosterone bio-adhesive gel, and primary and secondary efficacy and safety endpoints
CA2904293A1 (en) 2013-03-04 2014-09-12 Function Promoting Therapies, Llc Methods and systems for the diagnosis and treatment of androgen disorders
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10213440B2 (en) * 2014-08-20 2019-02-26 Professional Compounding Centers Of America (Pcca) Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor
ES2864099T3 (es) * 2015-04-03 2021-10-13 Benuvia Therapeutics Llc Formulaciones de pulverización sublingual de sildenafilo
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
CA2994709A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
KR20180074707A (ko) * 2015-10-15 2018-07-03 모세 로고스니츠키 저 용량 경구 디피리다몰 조성물 및 이의 용도

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
US5231087A (en) * 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
JP3238389B2 (ja) * 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
WO1990010462A1 (en) * 1989-03-10 1990-09-20 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
NZ253409A (en) * 1992-06-11 1996-09-25 Theratech Inc Drug delivery system; transdermal/transmucosal system using glycerine to moderate drug delivery
BR9306564A (pt) * 1992-06-19 1999-01-12 Univ California Processo para o tratamento da epiderme de um mamífero terrestre sofrendo de uma condição constitída por uma função de barreira epidérmica perturbada
DE4223004A1 (de) * 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US5885565A (en) * 1993-03-19 1999-03-23 Cellegy Pharmaceuticals Inc. Methods for inducing phase separation of epithelial lipid bilayers
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
NZ293849A (en) * 1994-09-14 1998-10-28 Minnesota Mining & Mfg Transdermal delivery matrix comprising a macromonomer containing acrylate or metacrylate copolymer, a softener and a drug
US5730987A (en) * 1996-06-10 1998-03-24 Omar; Lotfy Ismail Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
CN1231592A (zh) * 1996-10-30 1999-10-13 瑟垃技术有限公司 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6319913B1 (en) * 1997-11-10 2001-11-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002017927A1 (en) * 2000-08-30 2002-03-07 Unimed Pharmaceuticals, Inc. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
US20060088579A1 (en) * 2002-02-07 2006-04-27 Shastri Venkatram P Transdermal drug delivery systems
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20070082039A1 (en) * 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug

Similar Documents

Publication Publication Date Title
JP2006505587A5 (ja)
JP2004524267A5 (ja)
JP2017057230A5 (ja)
JP2007538008A5 (ja)
JP2005512995A5 (ja)
JP2005515964A5 (ja)
JP2005503322A5 (ja)
JP2004538303A5 (ja)
JP2004506682A5 (ja)
JP2006514949A5 (ja)
JP2008514557A5 (ja)
JP2002537232A5 (ja)
HUP0104652A2 (hu) Nátrium/hidrogén-csere inhibitorok alkalmazása öregkori szervi rendellenességek és öregkori betegségek megakadályozására és az élet meghosszabbítására alkalmas gyógyszerkészítmények előállítására
NO20052562L (no) Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte.
JP2005047851A5 (ja)
JP2008540603A5 (ja)
JP2005513105A5 (ja)
US20100190810A1 (en) Composition and method for treatment of warts
EP4364738A3 (en) Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US20060287364A1 (en) Methods of prevention of infection with HIV/AIDS, venereal disease and influenza
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
HUP0303754A2 (hu) Gyökfogó vegyületek alkalmazása NO-függő mikrokeringési zavarok kezelésére és megelőzésére szolgáló gyógyszerkészítmény előállítására
JP2006515607A5 (ja)
JP2004520279A5 (ja)
JP2003267863A5 (ja)